242 related articles for article (PubMed ID: 23718915)
21. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment.
Chan TS; Hwang YY; Gill H; Au WY; Leung AY; Tse E; Chim CS; Loong F; Kwong YL
Clin Transplant; 2012; 26(5):679-83. PubMed ID: 22324300
[TBL] [Abstract][Full Text] [Related]
22. Thoracic presentations of posttransplant lymphoproliferative disorders.
Halkos ME; Miller JI; Mann KP; Miller DL; Gal AA
Chest; 2004 Dec; 126(6):2013-20. PubMed ID: 15596707
[TBL] [Abstract][Full Text] [Related]
23. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
[TBL] [Abstract][Full Text] [Related]
24. Primary cutaneous CD30(+) lymphoproliferative disorders.
Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous Lymphomas - Part I: Mycosis Fungoides, Sézary Syndrome, and CD30
Pujol RM; Gallardo F
Actas Dermosifiliogr (Engl Ed); 2021 Jan; 112(1):14-23. PubMed ID: 32896500
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of cutaneous lymphomas in Osaka, Japan (1988-1999) based on the European Organization for Research and Treatment of Cancer classification.
Nagasawa T; Miwa H; Nakatsuka S; Itami S; Yoshikawa K; Aozasa K
Am J Dermatopathol; 2000 Dec; 22(6):510-4. PubMed ID: 11190442
[TBL] [Abstract][Full Text] [Related]
27. Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases.
Kikuchi A; Nishikawa T
Arch Dermatol; 1997 Jul; 133(7):829-33. PubMed ID: 9236520
[TBL] [Abstract][Full Text] [Related]
28. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
[TBL] [Abstract][Full Text] [Related]
29. Posttransplant Lymphoproliferative Disorder in Pediatric Patients: Characteristics of Disease in EBV-seropositive Recipients.
L'Huillier AG; Dipchand AI; Ng VL; Hebert D; Avitzur Y; Solomon M; Ngan BY; Yeung S; Stephens D; Punnett AS; Barton M; Allen UD
Transplantation; 2019 Nov; 103(11):e369-e374. PubMed ID: 31385930
[TBL] [Abstract][Full Text] [Related]
30. Donor or recipient origin of posttransplant lymphoproliferative disorders following solid organ transplantation.
Kinch A; Cavelier L; Bengtsson M; Baecklund E; Enblad G; Backlin C; Thunberg U; Sundström C; Pauksens K
Am J Transplant; 2014 Dec; 14(12):2838-45. PubMed ID: 25307322
[TBL] [Abstract][Full Text] [Related]
31. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
Riddler SA; Breinig MC; McKnight JL
Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879
[TBL] [Abstract][Full Text] [Related]
32. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
33. Nodal Involvement by CD30
Lezama LS; Gratzinger D
Arch Pathol Lab Med; 2018 Jan; 142(1):139-142. PubMed ID: 29257929
[TBL] [Abstract][Full Text] [Related]
34. Impact of the posttransplant lymphoproliferative disorder subtype on survival.
Koff JL; Li JX; Zhang X; Switchenko JM; Flowers CR; Waller EK
Cancer; 2018 Jun; 124(11):2327-2336. PubMed ID: 29579330
[TBL] [Abstract][Full Text] [Related]
35. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
36. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA
Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
[TBL] [Abstract][Full Text] [Related]
37. Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma?
Ranganathan S; Webber S; Ahuja S; Jaffe R
Pediatr Dev Pathol; 2004; 7(4):348-60. PubMed ID: 14564542
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous lymphoproliferative disorders: Back to the future.
Willemze R
J Cutan Pathol; 2024 Jun; 51(6):468-476. PubMed ID: 38499969
[TBL] [Abstract][Full Text] [Related]
39. Frequency of primary cutaneous lymphoma variants in Austria: retrospective data from a dermatology referral centre between 2006 and 2013.
Eder J; Kern A; Moser J; Kitzwögerer M; Sedivy R; Trautinger F
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1517-23. PubMed ID: 25600184
[TBL] [Abstract][Full Text] [Related]
40. Signet ring cell primary cutaneous CD30+ lymphoproliferative disorder presenting as a monomorphic T-cell posttransplant lymphoproliferative disease.
Papalas JA; Kulbacki EL; Park HK; Howell ER
Am J Dermatopathol; 2012 Oct; 34(7):e94-6. PubMed ID: 22534639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
